Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection

Table 2 Outcomes of 1-wk and 2-wk moxifloxacin-containing triple therapy n (%)

	1-wk MCT	2-wk MCT	P value
Eradication rate
Intention-to-treat	34 (56.7)	29 (76.3)	0.048
Per-protocol	34 (59.6)	29 (80.6)	0.036
Compliance	57 (95.0)	36 (94.9)	0.954
Side effects	12 (21.1)	5 (13.9)	0.384
Nausea	5 (11.6)	0	0.178
Dyspepsia	4 (7.0)	1 (2.8)
Epigastric soreness	2 (3.5)	1 (2.8)
Diarrhea	1 (1.8)	3 (8.3)

MCT: Moxifloxacin-containing triple therapy.